The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hematocrit


Psychiatry related information on Hematocrit


High impact information on Hematocrit

  • Patients were categorized according to the hematocrit on admission (5.0 to 24.0 percent, 24.1 to 27.0 percent, 27.1 to 30.0 percent, 30.1 to 33.0 percent, 33.1 to 36.0 percent, 36.1 to 39.0 percent, or 39.1 to 48.0 percent), and data were evaluated to determine whether there was an association between the use of transfusion and 30-day mortality [11].
  • CONCLUSIONS: In patients receiving hemodialysis, subcutaneous administration of epoetin can maintain the hematocrit in a desired target range, with an average weekly dose of epoetin that is lower than with intravenous administration [12].
  • CONCLUSIONS: In patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended [5].
  • The hematocrit was measured weekly for four weeks, transferrin saturation was measured, and coexisting illnesses were documented [13].
  • To determine the effect of an increased level of dialysis on the hematocrit, the thrice-weekly schedule of dialysis was increased to raise the mean urea-reduction value from 60.7 to 72 percent for six weeks in 20 consecutive patients whose base-line urea-reduction value was less than 65 percent [13].

Chemical compound and disease context of Hematocrit


Biological context of Hematocrit


Anatomical context of Hematocrit

  • The recombinant human erythropoietin was given intravenously three times weekly after dialysis, and transfusion requirements, hematocrit, ferrokinetics, and reticulocyte responses were monitored [2].
  • We report two cases in intravenous methamphetamine users who presented with abnormal liver function values, low hematocrit values, basophilic stippling of red blood cells, and elevated blood lead levels [24].
  • With EPO administration, cisplatin-treated rats exhibit a greater reticulocyte response and hematocrit increment then non-cisplatin-treated rats given EPO, indicating minimal erythroid precursor cell damage from cisplatin [25].
  • Importantly, cardioprotective effects of EPO were seen without an increase in hematocrit (eliminating oxygen delivery as an etiologic factor in myocyte survival and function), demonstrating that EPO can directly protect the ischemic and infarcted heart [26].
  • Bone marrow cellularity, hematocrit values, white blood cell counts, and splenic hematopoietic progenitor cell content were all significantly increased if rhGH (20 micrograms injected intraperitoneally every other day) was concurrently administered with AZT [27].

Associations of Hematocrit with chemical compounds

  • The rate of the decline in renal function, as measured by serial determination of the reciprocal of the serum creatinine level, did not change significantly as the hematocrit rose (P = 0.78 by the paired t-test) during erythropoietin therapy [28].
  • The change in the hematocrit in these patients was compared with that observed in the next 20 patients who had an equivalent base-line urea-reduction value but whose level of dialysis was not altered [13].
  • The response to nandrolone and testosterone enanthate, the two drugs given by injection, was clearly superior to the response to oxymetholone or fluoxymesterone, given by mouth, in terms of the percentage of patients responding and the mean rise in hematocrit [29].
  • Approximately half the patients had an increase of at least 5 percentage points in hematocrit after an injectable androgen was given; more than half the women responded [29].
  • In contrast, less intensive exercise (800-m swim lasting ten minutes and resulting in a sevenfold rise in the level of blood lactate) failed to cause a rise in serum sodium level despite comparable elevations in hematocrit reading and serum protein levels [30].

Gene context of Hematocrit


Analytical, diagnostic and therapeutic context of Hematocrit


  1. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. Rao, D.S., Shih, M.S., Mohini, R. N. Engl. J. Med. (1993) [Pubmed]
  2. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W. N. Engl. J. Med. (1987) [Pubmed]
  3. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. Cotes, P.M., Doré, C.J., Yin, J.A., Lewis, S.M., Messinezy, M., Pearson, T.C., Reid, C. N. Engl. J. Med. (1986) [Pubmed]
  4. Analysis of risk factors for stroke in a cohort of men born in 1913. Welin, L., Svärdsudd, K., Wilhelmsen, L., Larsson, B., Tibblin, G. N. Engl. J. Med. (1987) [Pubmed]
  5. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, D.M., Schwab, S.J., Goodkin, D.A. N. Engl. J. Med. (1998) [Pubmed]
  6. Glomerular filtration and fluid balance in genetically hypertensive mice. Rosenberg, W.L., Schlager, G., Gennaro, J.F. Proc. Soc. Exp. Biol. Med. (1985) [Pubmed]
  7. Determinants of plasma uric acid. Gulbrandsen, C.L., Morton, N.E., Rao, D.C., Rhoads, G.G., Kagan, A. Hum. Genet. (1979) [Pubmed]
  8. Effects of water deprivation and rehydration on c-Fos and FosB staining in the rat supraoptic nucleus and lamina terminalis region. Ji, L.L., Fleming, T., Penny, M.L., Toney, G.M., Cunningham, J.T. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) [Pubmed]
  9. Plasma lipids and lipoproteins in elderly Japanese-American men. Curb, J.D., Reed, D.M., Yano, K., Kautz, J.A., Albers, J.J. Journal of the American Geriatrics Society. (1986) [Pubmed]
  10. Continuous infusion of endotoxin from an osmotic pump in the conscious, unrestrained rat: a unique model of chronic endotoxemia. Fish, R.E., Spitzer, J.A. Circ. Shock (1984) [Pubmed]
  11. Blood transfusion in elderly patients with acute myocardial infarction. Wu, W.C., Rathore, S.S., Wang, Y., Radford, M.J., Krumholz, H.M. N. Engl. J. Med. (2001) [Pubmed]
  12. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. Kaufman, J.S., Reda, D.J., Fye, C.L., Goldfarb, D.S., Henderson, W.G., Kleinman, J.G., Vaamonde, C.A. N. Engl. J. Med. (1998) [Pubmed]
  13. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. Ifudu, O., Feldman, J., Friedman, E.A. N. Engl. J. Med. (1996) [Pubmed]
  14. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Elliott, S.N., McKnight, W., Cirino, G., Wallace, J.L. Gastroenterology (1995) [Pubmed]
  15. An animal model of fulminant hepatic failure: a feasibility study. Miller, D.J., Hickman, R., Fratter, R., Terblanche, J., Saunders, S.J. Gastroenterology (1976) [Pubmed]
  16. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Lim, V.S., DeGowin, R.L., Zavala, D., Kirchner, P.T., Abels, R., Perry, P., Fangman, J. Ann. Intern. Med. (1989) [Pubmed]
  17. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. D'Amico, G., De Franchis, R. Hepatology (2003) [Pubmed]
  18. Acute, chronic and terminal toxicity to 4'-demethylepipodophyllotoxin thenylidene glucoside (VM26) in mice. Hacker, M., Roberts, D.W. Cancer Res. (1975) [Pubmed]
  19. Continuous ambulatory peritoneal dialysis in children: comparison with hemodialysis. Baum, M., Powell, D., Calvin, S., McDaid, T., McHenry, K., Mar, H., Potter, D. N. Engl. J. Med. (1982) [Pubmed]
  20. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. Mannucci, P.M., Remuzzi, G., Pusineri, F., Lombardi, R., Valsecchi, C., Mecca, G., Zimmerman, T.S. N. Engl. J. Med. (1983) [Pubmed]
  21. Intestinal pacing for canine postgastrectomy dumping. Becker, J.M., Sava, P., Kelly, K.A., Shturman, L. Gastroenterology (1983) [Pubmed]
  22. Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass. Rice, L., Ruiz, W., Driscoll, T., Whitley, C.E., Tapia, R., Hachey, D.L., Gonzales, G.F., Alfrey, C.P. Ann. Intern. Med. (2001) [Pubmed]
  23. Preferential venoconstriction by cyclooxygenase inhibition in vivo without attenuation of nitroglycerin venodilation. Münzel, T., Stewart, D.J., Holtz, J., Bassenge, E. Circulation (1988) [Pubmed]
  24. Acute lead poisoning in two users of illicit methamphetamine. Allcott, J.V., Barnhart, R.A., Mooney, L.A. JAMA (1987) [Pubmed]
  25. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. Wood, P.A., Hrushesky, W.J. J. Clin. Invest. (1995) [Pubmed]
  26. A novel protective effect of erythropoietin in the infarcted heart. Parsa, C.J., Matsumoto, A., Kim, J., Riel, R.U., Pascal, L.S., Walton, G.B., Thompson, R.B., Petrofski, J.A., Annex, B.H., Stamler, J.S., Koch, W.J. J. Clin. Invest. (2003) [Pubmed]
  27. Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Murphy, W.J., Tsarfaty, G., Longo, D.L. Blood (1992) [Pubmed]
  28. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. Eschbach, J.W., Kelly, M.R., Haley, N.R., Abels, R.I., Adamson, J.W. N. Engl. J. Med. (1989) [Pubmed]
  29. A comparison of androgens for anemia in patients on hemodialysis. Neff, M.S., Goldberg, J., Slifkin, R.F., Eiser, A.R., Calamia, V., Kaplan, M., Baez, A., Gupta, S., Mattoo, N. N. Engl. J. Med. (1981) [Pubmed]
  30. Hypernatremia induced by maximal exercise. Felig, P., Johnson, C., Levitt, M., Cunningham, J., Keefe, F., Boglioli, B. JAMA (1982) [Pubmed]
  31. Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Galy, B., Ferring, D., Minana, B., Bell, O., Janser, H.G., Muckenthaler, M., Schümann, K., Hentze, M.W. Blood (2005) [Pubmed]
  32. Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3. Jegalian, A.G., Acurio, A., Dranoff, G., Wu, H. Blood (2002) [Pubmed]
  33. FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Meyer, D., Schiller, C., Westermann, J., Izui, S., Hazenbos, W.L., Verbeek, J.S., Schmidt, R.E., Gessner, J.E. Blood (1998) [Pubmed]
  34. Mild nephrogenic diabetes insipidus caused by Foxa1 deficiency. Behr, R., Brestelli, J., Fulmer, J.T., Miyawaki, N., Kleyman, T.R., Kaestner, K.H. J. Biol. Chem. (2004) [Pubmed]
  35. Effect of theophylline on erythrocytosis in chronic obstructive pulmonary disease. Oren, R., Beeri, M., Hubert, A., Kramer, M.R., Matzner, Y. Arch. Intern. Med. (1997) [Pubmed]
  36. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. Maier, R.F., Obladen, M., Scigalla, P., Linderkamp, O., Duc, G., Hieronimi, G., Halliday, H.L., Versmold, H.T., Moriette, G., Jorch, G. N. Engl. J. Med. (1994) [Pubmed]
  37. Office evaluation of hypertension. A statement for health professionals by a writing group of the Council for High Blood Pressure Research, American Heart Association. Gifford, R.W., Kirkendall, W., O'Connor, D.T., Weidman, W. Circulation (1989) [Pubmed]
  38. Dysregulated expression of GATA-1 following retrovirus-mediated gene transfer into murine hematopoietic stem cells increases erythropoiesis. Farina, S.F., Girard, L.J., Vanin, E.F., Nienhuis, A.W., Bodine, D.M. Blood (1995) [Pubmed]
  39. Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Rabinovici, R., Esser, K.M., Lysko, P.G., Yue, T.L., Griswold, D.E., Hillegass, L.M., Bugelski, P.J., Hallenbeck, J.M., Feuerstein, G. Circ. Res. (1991) [Pubmed]
  40. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Koury, S.T., Koury, M.J., Bondurant, M.C., Caro, J., Graber, S.E. Blood (1989) [Pubmed]
WikiGenes - Universities